EVERSANA's Vikram Anand breaks down FDA data on complete response letters, showing how gaps in pharmacovigilance and safety readiness, not manufacturing alone, drive costly delays in drug commercialization.
Vikram Anand
Advertisement
Vikram Anand is president of compliance services at EVERSANA.
Articles by Vikram Anand
Advertisement
Latest Updated Articles
Advertisement
Advertisement